Skip to main content
Annexon, Inc. logo

Annexon, Inc. — Investor Relations & Filings

Ticker · ANNX ISIN · US03589W1027 US Manufacturing
Filings indexed 468 across all filing types
Latest filing 2020-09-08 Earnings Release
Country US United States of America
Listing US ANNX

About Annexon, Inc.

https://annexonbio.com/

Annexon, Inc. is a clinical-stage biopharmaceutical company developing a new class of complement medicines. The company's therapeutic approach is centered on inhibiting C1q, the initiating molecule of the classical complement pathway. By blocking C1q at the start of this immune cascade, Annexon aims to prevent the inflammation and tissue damage that drive a range of diseases. Its pipeline is focused on developing treatments for classical complement-mediated disorders affecting the body, brain, and eye, which include autoimmune, neurodegenerative, and ophthalmic conditions.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 8, 2020, reporting the company's financial results for the second quarter ended June 30, 2020. It includes a press release titled 'Annexon Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights' as an exhibit. The text does not contain the full financial statements or detailed financial analysis itself but rather announces the results and furnishes the press release. The document length is 3822 characters, which is relatively short and consistent with an earnings release announcement rather than a full report. According to the rules, initial announcements of quarterly financial results with key highlights only are classified as Earnings Release (ER).
2020-09-08 English
10-Q
Interim / Quarterly Report Q2 2020
2020-09-08 English
SC 13D
Major Shareholding Notification
2020-08-07 English
SCHEDULE 13G
Major Shareholding Notification
2020-08-07 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-08-07 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-07-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.